274 related articles for article (PubMed ID: 217121)
1. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
Therapie; 1978; 33(5):615-22. PubMed ID: 217121
[No Abstract] [Full Text] [Related]
2. Effect of hypolipidemic drugs on serum lipoproteins.
Carlson LA; Olsson AG
Prog Biochem Pharmacol; 1979; 15():238-57. PubMed ID: 224397
[No Abstract] [Full Text] [Related]
3. [Beta-sitosterin in unsuccessfully pretreated patients with hypercholesteremia. Simultaneously, a contribution to dose dependence].
Mühlfellner G; Mühlfellner O; Kaffarnik H
Med Klin; 1976 Apr; 71(18):775-8. PubMed ID: 178987
[TBL] [Abstract][Full Text] [Related]
4. Should hyperlipoproteinemia be treated in patients with coronary artery disease?
Rider AK
JAMA; 1975 Jul; 233(3):275-7. PubMed ID: 168412
[No Abstract] [Full Text] [Related]
5. Bile acid metabolism in hyperlipoproteinaemia.
Hellström K; Einarsson K
Clin Gastroenterol; 1977 Jan; 6(1):103-28. PubMed ID: 196796
[No Abstract] [Full Text] [Related]
6. Dietary and drug treatment of primary hyperlipoproteinemia.
Ann Intern Med; 1972 Aug; 77(2):267-94. PubMed ID: 4345081
[No Abstract] [Full Text] [Related]
7. Cholestyramine for elevated serum cholesterol.
Med Lett Drugs Ther; 1974 Apr; 16(8):33-4. PubMed ID: 4362570
[No Abstract] [Full Text] [Related]
8. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Orö L; Olsson AG; Rössner S; Carlson LA
Postgrad Med J; 1975; 51(8):76-81. PubMed ID: 176639
[No Abstract] [Full Text] [Related]
9. [Treatment of hyperlipoproteinemias (author's transl)].
Crepaldi G; Fellin R; Briani G; Baggio G; Baiocchi MR
G Ital Cardiol; 1974; 4(3):332-40. PubMed ID: 4367439
[No Abstract] [Full Text] [Related]
10. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
Haacke H; Parwaresch MR; Mäder C
Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168
[TBL] [Abstract][Full Text] [Related]
11. Differential drug therapy of the hyperlipoproteinaemias. Physiological rationale for differential drug therapy.
Levy RI
Postgrad Med J; 1975; 51(8):suppl 60-2. PubMed ID: 215982
[No Abstract] [Full Text] [Related]
12. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Orö L; Olsson AG; Rössner S; Carlson LA
Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
[TBL] [Abstract][Full Text] [Related]
13. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of Type II and Type IV hyperlipoproteinemia in the office practice setting.
Millett F; Sielski J; Stoll H; Alston N; Gail S
PA J; 1976; 6(2):54-9. PubMed ID: 10235781
[No Abstract] [Full Text] [Related]
15. Pseudohomozygous type II hyperlipoproteinemia.
Morganroth J; Levy RI; McMahon AE; Gotto AM
J Pediatr; 1974 Nov; 85(5):639-43. PubMed ID: 4370845
[No Abstract] [Full Text] [Related]
16. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
Klemens UH; von Löwis P
Dtsch Med Wochenschr; 1973 Jun; 98(24):1197-202. PubMed ID: 4350685
[No Abstract] [Full Text] [Related]
17. Hypercholesterolemia: new values, new strategies.
Lueg MC; Anding RH
Hosp Pract (Off Ed); 1986 Jan; 21(1A):112-3, 116-7, 120-2. PubMed ID: 3080456
[No Abstract] [Full Text] [Related]
18. Clinical evaluation of cinnarizine in hyperlipaemic patients.
Saba P; Galeone F; Salvadorini F; Guarguaglini M; Houben JL
G Clin Med; 1974 Aug; 55(8):586-99. PubMed ID: 4377134
[No Abstract] [Full Text] [Related]
19. Xanthomatosis and hyperlipoproteinemia; a review.
Polano MK
Dermatologica; 1974; 149(1):1-9. PubMed ID: 4372111
[No Abstract] [Full Text] [Related]
20. Response of hyperlipoproteinemia to cholestyramine resin.
Fallon HJ; Woods JW
JAMA; 1968 Jun; 204(13):1161-4. PubMed ID: 5694692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
